RCTs of therapies in severe asthma: poorly generalisable

A new study published in the European Respiratory Journal has found that randomised controlled trials (RCTs) of biological therapies in severe asthma are poorly generalisable, with most patients excluded by outdated disease concepts, despite possessing the targetable trait addressed by the treatment. Read the study here or visit erj.ersjournals.com to browse the issue.